Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

August 7th 2023

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Management of Diffuse Large B-Cell Lymphoma: Data From ASCO 2023

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 31st 2023

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, The University of Texas MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 31st 2023

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Bridging Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 24th 2023

Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.

Sequencing Novel Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 24th 2023

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

What is the Role of Bispecifics in Relapsed/Refractory DLBCL?

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 17th 2023

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

Relapsed/Refractory DLBCL: Managing Patients on CAR T-Cell Therapy

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 17th 2023

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

Factors That Inform Sequencing of Therapy in Relapsed/Refractory DLBCL

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 10th 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Real-World Use of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 10th 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Lisocabtagene Maraleucel

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 3rd 2023

A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

CAR T-Cell Therapy in Relapsed/Refractory DLBCL: Axicabtagene Ciloleucel

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

July 3rd 2023

Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.

Tafasitamab + Lenalidomide Therapy in Relapsed/Refractory DLBCL

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

June 26th 2023

Panelists review data behind the combination of tafasitamab and lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Factors in Selecting Treatment for Relapsed/Refractory DLBCL

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

June 26th 2023

Focused discussion on specific patient or disease factors that aid in the selection of therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Overview of Relapsed/Refractory DLBCL and Management Strategies

Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Joanna M. Rhodes, MD, MSCE;Yucai Wang, MD, PhD, Mayo Clinic;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Hayder M. Saeed, MD, Moffitt Cancer Center

June 19th 2023

Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.

Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma

Joanna M. Rhodes, MD, MSCE;Jason Westin, MD, MS, FACP, MD Anderson Cancer Center;Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Yucai Wang, MD, PhD, Mayo Clinic;Hayder M. Saeed, MD, Moffitt Cancer Center

June 19th 2023

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.

Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute

Articles

Latest Updated Articles

Latest Conference Coverage